Hypoxic pulmonary vasoconstriction (HPV) is an important
homeostatic mechanism in which increases of [Ca2+]i are primary
events. In this study, primary cultured, human pulmonary artery
smooth muscle cells (hPASMC) were used to examine the role of
TRPC channels in mediating [Ca2+]i elevations during hypoxia.
Hypoxia (PO2 about 20 mm Hg) evoked a transient [Ca2+]i elevation
that was reduced by removal of extracellular calcium. Nifedipine
and verapamil, blockers of voltage-gated calcium channels
(VGCCs), attenuated the hypoxia-induced [Ca2+]i elevation by
about 30 %, suggesting the presence of alternate Ca2+ entry
pathways. Expression of TRPC1 and TRPC6 in hPASMC were found
by RT-PCR and confirmed by Western blot analysis. Antagonists for
TRPC, 2APB and SKF96365, significantly reduced hypoxia-induced
[Ca2+]i elevation by almost 60 %. Both TRPC6 and TRPC1 were
knocked down by siRNA, the loss of TRPC6 decreased hypoxic
response down to 21 % of control, whereas the knockdown of
TRPC1 reduced the hypoxia response to 85 %, suggesting that
TRPC6 might play a central role in mediating hypoxia response in
hPASMC. However, blockade of PLC pathway caused only small
inhibition of the hypoxia response. In contrast, AICAR, the agonist
of AMP-activated kinase (AMPK), induced a gradual [Ca2+]i
elevation, whereas compound C, an antagonist of AMPK, almost
abolished the hypoxia response. However, co-immunoprecipitation
revealed that AMPKα was not colocalized with TRPC6. Our data
supports a role for TRPC6 in mediation of the [Ca2+]i elevation in
response to hypoxia in hPASMC and suggests that this response
may be linked to cellular energy status via an activation of AMPK.